



In this index, *f* denotes figure, *s* denotes sidebar, and *t* denotes table.

A

- AAC. *See* Augmentative or alternative communication (AAC)
- Abandoned utterances, 200
- ABCD. *See* *Arizona Battery for Communication Disorders of Dementia* (ABCD)
- ABS. *See* *Affect Balance Scale* (ABS)
- Abstract letter identification, 16*f*, 17
- Accommodations. *See also* Compensatory strategies; Interpreters; Modifications, 122, 129, 131–132, 149, 152
- Accreditation agencies, 122, 279, 281, 283
- Acetylcholine. *See also* Cholinergic system, 397*s*, 402
- Achromatopsia, 55*t*, 73, 152
- Acoustic environment, 448–449
- Acoustic-phonological conversion, 15, 16*f*
- Acquired dysgraphia, 41
- Acquired dyslexia, 40–41
- Acquired immune deficiency syndrome (AIDS), 93
- Activity and participation. *See also* Assessments of activity, participation, and quality of life, 3–4, 5, 488
- Activity-focused treatment. *See also* Participation-focused treatment, 412–425, 426*f*, 427–451
- Acupuncture, 461–462
- Acute-care settings
- assessment goals in, 117, 117*t*
 - assessment restrictions in, 135, 136
 - hidden deficits due to, 59–60
 - observations in, 167
 - overview of, 474–477
 - patient interview and limitations from, 128
 - process measures and, 279–280*s*
- AD. *See* Alzheimer's disease (AD)
- AD8 Dementia Screening Interview, 229
- ADA. *See* Americans with Disabilities Act (1990)
- Adaptive treatment. *See* Accommodations; Compensatory strategies; Modifications; Restorative versus adaptive treatment
- ADD. *See* *Auditory Discrimination in Depth* (ADD)

- Adolescents. *See also* Children, 150, 182–183, 198, 206, 209, 259, 262
- Advocacy
 in assessment procedures, 116, 122
 for referrals and services, 123–124, 149, 299–300, 423s, 490
 for self, 379
 for treatment intensity, 355
 for use of AAC, 422–423
- Affect Balance Scale (ABS)*, 290–291
- Affordable Care Act (2010), 482
- A-FROM. *See Living With Aphasia: Framework for Outcome Measurement (A-FROM)*
- Age, as a testing confound, 214
- Age, as prognostic factor, 216t, 217, 267–268
- Ageism, 217
- Aging population, differential diagnostic difficulties in, 112
- Agitation. *See* Disruptive behaviors
- Agonists, 397
- Agrammatism, 37t, 38, 39f, 335, 337, 338
- Agraphia, 41, 42t, 51
- Agraphia treatment. *See* Orthographic treatment approaches
- AIDS, 93
- Akinetopsia, 152
- ALA. *See Assessment for Living With Aphasia (ALA)*
- Alcohol abuse, 110, 111
- Alexia, 40–41, 42t, 51
- Alexia treatment. *See* Orthographic treatment approaches
- ALFA. *See Assessment of Language-Related Functional Activities (ALFA)*
- Allesthesia, 57–58
- Allographic conversion deficits, 309
- AllTalk, 421
- Alphabet search, 369
- Alzheimer's disease (AD). *See also* Dementia
 angular gyrus syndrome versus, 111
 causes of, 103–105
 complicating conditions in, 152, 157, 159
 diagnosing, 103, 104t, 112
 lesion location for, 73s
 perceptual deficits in, 73
 Pick's disease versus, 105
 PPA and, 52
 prevalence of, 102
 prognostic factors in, 270
 pseudodementia versus, 112
 quality-of-life measures for, 293
 risk and protective factors for, 102, 103t
 symptoms of, 22, 74, 75–76, 219
- Alzheimer's Disease Caregiver's Questionnaire*, 232
- Alzheimer's disease tests, 184, 206, 208, 212, 232
- Alzheimer's disease treatment. *See also* Behavioral approaches for cognitive disorders
 CAM, 458, 460, 462, 463, 464
 memory treatment, 373, 374

- pharmacotherapy approaches, 399–400*t*, 405, 406, 407, 408
 - taped autobiographical narratives, 368
- Alzheimer's Quick Test*, 232–233
- Amantadine, 399*t*, 405
- American Heart Association, 36
- American Sign Language (ASL), 416
- American Speech-Hearing Association (ASHA)
 - on advocacy, 490
 - on documentation, 488
 - on EBP, 10–11*s*
 - ICF and, 2
 - on practice economics, 487
 - on prevention activities, 470*s*
 - program evaluations by, 281, 282*t*
 - quality-of-life measures by, 293
 - on SLPAs, 487
 - support organization resources, 456
- Americans With Disabilities Act (1990), 448, 482
- Amer-Ind signs, 213, 416–417
- Amnesia. *See* Post-traumatic amnesia (PTA)
- Amphetamines, 399–400*t*, 401–402
- Amusia, 150
- Aneurysms, 88, 88*f*
- Angular gyrus, 29
- Angular gyrus syndrome, 111
- Anomia, 38–40, 41, 71
- Anomia treatment, 391
- Anomic aphasia, 48*t*, 50, 51, 221
- Anosodiaphoria, 59
- Anosognosia
 - assessments for, 264–265
 - definition of, 59
 - in frontotemporal dementia, 75
 - functional outcomes of, 226
 - as prognostic factor, 222, 270
 - in TBI, 228
- Antagonists, 397
- Anterograde amnesia, 69–70
- Anterograde memories, 22, 31
- Anticipatory awareness deficit, 70
- Antipsychotic medications, 400*t*, 407–408
- Anxiety, 220
- Aphasia
 - A-FROM and, 275*s*
 - apraxia of speech versus, 153–154
 - classification systems for, 46–47, 48*t*, 49–52, 179
 - complicating conditions after, 150, 153
 - contextual variability of, 133
 - definition and prevalence of, 36, 49, 50, 51
 - explanations of, 45–46

- frontotemporal dementia and, 63–64s
- patient interview and limitations from, 128
- prognostic factors in, 219, 220–221
- psychiatric disorders screenings and, 160
- symptoms of, 36–45
- types of, 50–52, 53*t*
- Aphasia groups, 437
- Aphasia screenings, 172*t*, 173
- Aphasia tests. *See also* Lexical–semantic processing tests; Morphosyntactic processing tests; Orthographic processing tests; Phonological processing tests; *specific tests*
 - dementia patients and use of, 183–184
 - overview of, 175–179, 185, 191, 198, 212
 - RHD tests versus, 180
 - TBI tests versus, 183
- Aphasia treatment. *See also* Lexical–semantic treatment approaches; Morphosyntactic treatment approaches; Orthographic treatment approaches; Phonological treatment approaches
 - AAC considerations in, 419–420, 421–422
 - Amer-Ind signs, 417
 - APT, 364, 390
 - CAM, 458, 461–462, 464
 - in groups, 437
 - PACE, 432–434
 - pharmacotherapy approaches, 399–400*t*, 401–403, 408
 - SCA, 443–444
 - sentence repetition tasks, 390
 - variables for consideration in, 37
- Applications (Apps). *See also* Software and applications, as treatment activities, 421–422
- Apraxia Battery for Adults–Second Edition*, 153, 157, 213
- Apraxia of speech, 128, 153–154
- APT. *See* *Attention Process Training* (APT)
- Arcuate fasciculus, 29
- Arizona Battery for Communication Disorders of Dementia* (ABCD), 176*t*, 184
- Arteriovenous malformation (AVM), 88–89
- ASHA. *See* American Speech-Hearing Association (ASHA)
- ASHA Functional Assessment of Communication Skills for Adults* (ASHA FACS), 281, 283, 285
- ASHA QCL. *See* *Quality of Communication Life Scale* (ASHA QCL)
- ASL. *See* American Sign Language (ASL)
- Assessment confounds. *See* Complicating conditions
- Assessment for Living With Aphasia* (ALA), 295, 296*f*
- Assessment of Communicative Effectiveness in Severe Aphasia*, 176*t*, 178
- Assessment of Intelligibility of Dysarthric Speech*, 154
- Assessment of Language-Related Functional Activities* (ALFA), 176*t*, 284–285
- Assessment of Nonverbal Communication*, 213
- Assessment procedures, 124–144, 166, 171–174
- Assessments. *See also* Cognitive disorders assessment of body structure and function; Linguistic disorders assessment of body structure and function; *specific tests*
 - in acute care, 473, 475–476
 - approach considerations for, 119–123
 - goals of, 116, 117–119, 121s
 - non-standardized procedures in, 476s

- in outpatient settings, 480
 - in rehabilitation phase, 478
 - reimbursement issues with, 116s
 - sharing results of, 144–145
- Assessments of activity, participation, and quality of life
 - approach considerations for, 278–279
 - authentic assessment and ethnography, 295, 297–298
 - environmental factors and, 448
 - functional measures for, 279–286
 - importance of, 273–274, 288–289
 - list of measures by population, 276–277*t*
 - participation measures, 286–288
 - quality-of-life measures, 289–294
 - relationship among measures, 294–295, 296*f*
 - term definitions in, 274–275
- Association areas and fibers, 29
- Ataxia, 158
- Attention, 19–20, 30–31
- Attention deficits
 - with aphasia, 43
 - in dementia, 74
 - in RHD, 54, 56–58, 60, 62
 - in TBI, 68–69
- Attention Process Training* (APT), 363, 364
- Attention Process Training–II* (APT-II), 363, 364, 366, 390
- Attention Process Training–III* (APT-III), 363, 364, 364*t*, 366
- Attention switching, 20, 20*t*, 31
- Attention tests, 233, 239–240, 248–252
- Attention treatment. *See also* Intention treatment
 - attention training or retraining, 360, 363–365, 390
 - cognitive strategies, 424
 - combined approaches, 366–367
 - for neglect, 358–363
 - strategy training, 365
- Audiologists, 148, 150, 449
- Audiology, 120*t*
- Audio recordings, 368, 378, 380
- Auditory agnosias, 55*t*, 73–74, 150
- Auditory Discrimination in Depth* (ADD), 304*t*
- Auditory perceptual deficits screenings, 150, 151*t*
- Auditory phonological analysis, 15, 16*f*
- Auditory sound agnosia, 150
- Auditory-verbal working memory tests, 253–254
- Auditory word-picture matching, 302
- Augmentative or alternative communication (AAC). *See also* External devices, 418–422
- Authentic assessment and ethnography, 295, 297–298
- Authentic context, 454
- Autobiographical memory. *See also* Episodic memory, 58
- Autopagnosia, 152
- AVM. *See* arteriovenous malformation (AVM)

Awareness training, 377–378, 379*t*, 380
 Axonal shearing, 98, 99*f*

B

Back to the Drawing Board, 413
 Backward chaining, 373
 Bacterial meningitis, 92
 BADS. *See Behavioral Assessment of Dysexecutive Syndrome (BADS)*
 Balanced Budget Act of 1997, 484
Balloons Test, 250, 251
Barkley Deficits in Executive Functioning Scale (BDEFS), 243
 Barotraumas. *See Blast injuries*
 Barrier games, 345–346, 433
 BASA. *See Boston Assessment of Severe Aphasia (BASA)*
 Basal ganglia, 29, 30*f*, 31, 33, 83
 Basement effect, 239
 BAT. *See Bilingual Aphasia Test (BAT)*
 BDAE. *See Boston Diagnostic Aphasia Examination (BDAE)*
 BDAE-3. *See Boston Diagnostic Aphasia Examination—Third Edition (BDAE-3)*
 BDEFS. *See Barkley Deficits in Executive Functioning Scale (BDEFS)*
 BEAC. *See Behavior, Emotion, Attitude, and Communication questionnaire (BEAC)*
Bedside Evaluation Screening Test of Aphasia—Second Edition (BEST-2), 173
 Behavior, Emotion, Attitude, and Communication questionnaire (BEAC), 291
 Behavioral approaches for cognitive disorders, 357–392
 Behavioral approaches for linguistic disorders, 299–355
Behavioral Assessment of Dysexecutive Syndrome (BADS), 229, 242
Behavioral Inattention Test (BIT), 251
Behavior Rating Inventory of Executive Function—Adult Version (BRIEF-A), 243
 Benign brain tumors, 91
 BEST-2. *See Bedside Evaluation Screening Test of Aphasia—Second Edition (BEST-2)*
 Bifemelane hydrochloride, 399*t*, 402
 Bilingual aphasia, 51–52
Bilingual Aphasia Test (BAT), 176*t*, 178
 Bilingualism, 338–339*s*
 Bilingual speakers. *See also specific types of speakers*, 125, 142–143*s*, 173, 178
 Biofeedback, 458
 Biographical factors, in prognosis, 217–218, 267–268
 BIT. *See Behavioral Inattention Test (BIT)*
 Blast injuries, 96–97, 100, 148, 152
 Blood clots, 88, 97, 98*t*
 Blood supply, in brain, 80–84
 BNT. *See Boston Naming Test (BNT)*
 Board games, 350
 Body structure and body function, 2, 5
Booklet Category Test—Second Edition, 260
 Books, 467*t*
 BOSS. *See Burden of Stroke Scale (BOSS)*
Boston Assessment of Severe Aphasia (BASA), 176*t*, 178, 179
Boston Diagnostic Aphasia Examination (BDAE), 183, 381
Boston Diagnostic Aphasia Examination—Third Edition (BDAE-3), 47, 173, 176*t*, 177–178, 203
Boston Naming Test (BNT), 121*s*, 138, 197
 From *Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice*, 2nd Ed.,
 by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.

Boston Naming Test—Second Edition, 178
 Bradykinesia, 158
 Brain. *See* Blood supply, in brain; Neuroanatomy
 Brain abscesses, 92–93
 Brain attacks. *See also* Strokes, 89
 Brain-behavior relationships, 25–27s
 Brain damage. *See* Primary brain damage; Secondary brain damage; *specific conditions*
 Brain stimulation approaches, 331–332
 Brain tumors, 90–92, 113, 219, 374
 BRIEF-A. *See* *Behavior Rating Inventory of Executive Function—Adult Version* (BRIEF-A)
Brief Test of Head Injury (BTHI), 176t, 182
 Broca’s aphasia. *See also* Expressive aphasia, 48t, 49, 221, 338, 464
 Broca’s area, 28, 29s, 31, 83
 Bromocriptine, 399t, 401
 BTHI. *See* *Brief Test of Head Injury* (BTHI)
 Bubble maps. *See* Metaphor Training Program (MTP)
Burden of Stroke Scale (BOSS), 292
Burns Brief Inventory of Communication and Cognition, 176t, 180–181

C

CADL-2. *See* *Communicative Activities of Daily Living—Second Edition* (CADL-2)
Calibrated Ideational Fluency Assessment (CIFA), 264
California Verbal Learning Test—Second Edition (CVLT-2). *See also* *Rey’s Visual Design Learning Test* (RVDLT), 252–253
 CAM. *See* Complementary and alternative medicine (CAM)
Cambridge Prospective Memory Test, 255
 Cancellation tasks, 249, 251, 360, 362
 Canonical word order, 18, 203
 Cantonese speakers, 197
 Capitation systems, 485
 Caps or limits, 484, 486
Caregiver-Administered Communication Inventory, 167
 Caregiver assessments, 143–144
 Caregiver attitudes, 216t, 218, 460
 Caregiver burden, 143, 226
 Caregiver education. *See also* Counseling and education; Family education
 assessment results sharing and, 145
 communication partner training, 210, 415, 440–448, 454
 on environmental modifications, 448–451
 on external devices use, 427, 431–432
 in home health care, 480
 on memory books, 428–430
 prognosis and, 219
 relaxation therapy and, 459
 on spaced retrieval, 371
 on strategies, 431–432
 on topic coherence and cohesion treatment, 347
 on treatment purposes, 301s, 354
 Caregivers. *See also* Families
 case history input of, 228
 functional measures and, 284
 From *Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice*, 2nd Ed., by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.

- observations of interactions with, 167
 - quality-of-life measures for, 293
 - screening input of, 174, 229, 232
 - workbooks and software use as respite for, 352
- Caregiver strategies, negative, 133, 144, 167
- CARF. *See* Commission on Accreditation of Rehabilitation Facilities (CARF)
- Carotid arterial system, 80–81, 82f, 83, 84
- CART. *See* Copy and Recall Treatment (CART)
- Case histories, 124–126, 167, 168–170f, 228–229
- Case-mix adjustment, 486
- Case rate systems, 485, 486
- CATE. *See* Complexity Account of Treatment Efficacy (CATE)
- Catecholamine system, 398, 401–402, 404–405
- Category Test*, 260
- Caudate nucleus, 30f, 31, 33, 109
- CC. *See* Coarse coding (CC)
- CDP. *See* Communicative Drawing Program (CDP)
- CELF-5. *See* *Clinical Evaluation of Language Fundamentals—Fifth Edition* (CELF-5)
- Cell phones. *See* iPhones; Smartphones
- Centers for Disease Control and Prevention (CDC), 94
- Centers for Medicare and Medicaid Services (CMS), 283, 482, 486
- Cerebellum, 31, 32f, 33
- Cerebral arteries. *See* Cerebral vascular system
- Cerebral hemispheres. *See also* Left hemisphere; Neuroanatomy; Right hemisphere, 81, 82f
- Cerebral vascular system, 80–84
- Cerebrovascular accidents. *See* Strokes
- CETI. *See* *Communicative Effectiveness Index* (CETI)
- Chaining techniques. *See also* Cueing hierarchies, 373–374, 375
- CHART. *See* *Craig Handicap Assessment and Reporting Technique* (CHART)
- Chemosensory impairments, 149–150
- Children. *See also* Adolescents
 - stroke incidence in, 85
 - TBI incidence and, 94, 95
 - tests for, 182–183, 208–209, 258, 262
 - tumor incidence in, 91
- Chinese speakers, 60, 178, 197, 265
- Cholinergic system, 402–403, 406
- CIAT. *See* Constraint-induced aphasia therapy (CIAT)
- CIFA. *See* *Calibrated Ideational Fluency Assessment* (CIFA)
- Cingulate gyrus, 31, 32f
- Circle of Willis, 83–84, 89
- Circumlocutions, 37t, 39, 40t, 200
- CIUs. *See* Correct information units (CIUs)
- Classical conditioning, 21f, 22
- Clinical competency
 - to advocate for referrals, 299–300
 - on formal test utility, 135, 136, 138–139, 140–141, 175, 184, 190
 - on range of communication, 349–350s
 - on workbook and software use, 353
- Clinical Evaluation of Language Fundamentals—Fifth Edition* (CELF-5), 182

- Clinical reasoning, 7, 11, 476
- Clinician-developed probe tasks, 171–172, 208, 209, 210, 213–214
- Clinician Interview-Based Impression of Change—Plus Caregiver Information* (CIBIC+), 132
- Clock Drawing, 233
- Closed class words, 202
- Closed head injuries. *See also* Traumatic brain injuries (TBI), 96, 97–98, 99f
- CLQT. *See Cognitive Linguistic Quick Test* (CLQT)
- CMS. *See* Centers for Medicare and Medicaid Services (CMS)
- Coarse coding (CC). *See also* Contextual Constraint Treatment, 341
- Cocaine abuse. *See* Substance abuse
- Cognistat*, 173
- Cognitive Change Checklist*, 232
- Cognitive-communicative disorders. *See also specific disorders*, 53–54, 71, 227s
- Cognitive-communicative disorders tests. *See also specific tests*, 140–141, 176–177t, 185
- Cognitive disorders. *See also specific disorders*, 8t, 111–113
- Cognitive disorders assessment of body structure and function. *See also specific tests*, 225–270
- Cognitive disorders treatment. *See* Activity-focused treatment; Behavioral approaches for cognitive disorders; Participation-focused treatment; Pharmacotherapy approaches
- Cognitive flexibility, 24, 32, 45
- Cognitive flexibility tests, 258, 262
- Cognitive functioning, general, tests for, 235, 236–237t, 238–239
- Cognitive inflexibility, 75
- Cognitive Linguistic Quick Test* (CLQT), 258, 265
- Cognitive neuropsychological approaches, 300–301, 322–330
- Cognitive outcomes and prognosis, 221–222
- Cognitive processing, 14, 18–24, 30–33, 42–45, 270
- Cognitive stimulation general approaches, 386–387
- Cognitive strategies, compensatory, 423–425
- Cognitive treatment, 390–392
- Cohesion analyses, 210–213
- Color Trails Test*, 248, 249
- Coma, 65
- Combine approaches, in attention remediation, 366
- Combined semantic and phonological treatment approaches, 330–331
- Commission on Accreditation of Rehabilitation Facilities (CARF), 122
- Common Objects Memory Test, 265
- Communication, 13–14
- Communication approaches, multimodality, 413–418
- Communication books. *See* Memory books
- Communication partners. *See also* Caregivers; Families
- AAC and, 418
 - in barrier games, 345–346
 - discourse sampling and, 210
 - memory books and, 430
 - in topic coherence and cohesion treatment, 347
 - training of, 415, 440–448, 454
- Communication symptoms. *See also* Aphasia, 59–63, 75–76, 216t, 219–220
- Communication systems, in ICUs, 473–474
- Communicative Activities of Daily Living—Second Edition* (CADL-2), 284–285
- Communicative Drawing Program (CDP), 413–414

- Communicative Effectiveness Index* (CETI), 132, 284
- Communicative Participation Item Bank*, 287–288
- Communicative Profiling System (CPS), 295, 297
- Community-based teams, 123s
- Community Integration Questionnaire* (CIQ), 286–287
- Community resources, 455–457
- Compensatory strategies. *See also* Accommodations; Modifications
 for activity-focused treatment, 412–434
 for allographic conversion deficits, 309
 group treatment and, 438
 lighthouse imagery strategy, 361
 metacognitive training, 358
 mnemonic strategies, 368–369
 practice of, 430–434
 strategy training, 365, 368–370
 for writing deficits, 311*t*
- Competency. *See* Clinical competency
- Complementary and alternative medicine (CAM), 457–464
- Complex Figure Test, 256
- Complexity Account of Treatment Efficacy (CATE), 337
- Complicating conditions
 observations of, 134
 overview of, 147–164
 as prognostic factors, 216*t*, 220, 222, 268–269
 sensitivity to, 229
- Comprehension deficits
 in aphasia, 37–38, 46–47
 figurative language approaches for, 342–344
 linguistic stimulation approaches for, 310–313
 phonological treatment approaches for, 329
 semantic treatment approaches for, 323–324
 suprasegmental impairments treatment for, 304–305
- Comprehensive Aphasia Test*, 176*t*
- Comprehensive Apraxia Test*, 153
- Comprehensive Receptive and Expressive Vocabulary Test—Third Edition* (CREVT-III), 198, 204
- Comprehensive Test of Nonverbal Intelligence—Second Edition* (CTONI-2), 262, 265
- Comprehensive Trail-Making Test*, 248
- Computer-Assisted Visual Communication system (C-VIC), 420
- Computerized tomography (CT scans), 26s
- Computers. *See* Software and applications, as treatment activities
- Conduction aphasia, 48*t*, 50, 221
- Confabulation, 61
- Confidentiality, 482
- Congruent overlap, 441
- Conjunctive devices, 211
- Connectionist classification systems, 47, 48*t*, 49–50
- Conners' Continuous Performance Test III*, 248
- Consciousness disorders, 65–67
- Constraint-induced aphasia therapy (CIAT), 355
- Construct validity, 136*t*, 137
- Content validity, 136–137
 From *Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice*, 2nd Ed.,
 by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.

- Contextual Constraint Treatment, 342, 343*f*
- Contextual factors. *See also* Environmental factors
- aphasia and, 37, 45
 - attention deficits and, 62
 - definitions of, 4
 - generalization and, 354
 - in home health care, 480
 - in LTC settings, 479
 - pragmatics and discourse impairments treatment and, 348–349
 - pragmatics and discourse processing and, 60–61, 340, 341
- Continuous quality improvement. *See* Program evaluations
- Continuous Visual Memory Test* (CVMT), 257
- Continuum of care, 470–481
- Contrastive stress procedures, 305, 306*t*
- Controlled Oral Word Association Test*, 263
- Conversation, CIUs and, 199
- Conversational rules, 18
- Conversational script training, 322, 454
- Conversational skills treatment, 347–348
- Conversation Analysis Profile for People With Aphasia*, 167
- Conversation Analysis Profile for People With Cognitive Impairment*, 167
- Conversation partners. *See* Communication partners
- Cooking tasks, 242–243
- Cooling therapy, 90
- Coping style, as prognostic factor, 269
- Coping With Aphasia*, 466
- Copy and Recall Treatment (CART), 313–314
- Copying tasks, 309–310
- Correct/incorrect judgments, 302
- Correct information units (CIUs), 199
- Cortical dementia. *See also* Dementia, 73*s*
- Cortical stimulation, 26*s*
- Cost effectiveness. *See* Health-care economics
- Counseling and education. *See also* Caregiver education; Family education; Patient education, 464–465, 467*t*, 468
- Coup and contrecoup injuries, 97–98, 99*f*
- Craig Handicap Assessment and Reporting Technique* (CHART), 286–287
- CREVT-III. *See* *Comprehensive Receptive and Expressive Vocabulary Test—Third Edition* (CREVT-III)
- Criterion-Oriented Test of Attention*, 248
- Criterion-related validity, 137
- Critical appraisals, 9, 10, 11
- Critical care units. *See* Intensive care units (ICUs)
- Critical thinking. *See also* Clinical reasoning, 7, 11, 476
- Crossed aphasia, 51
- CTONI-2. *See* *Comprehensive Test of Nonverbal Intelligence—Second Edition* (CTONI-2)
- CT scans. *See* Computerized tomography (CT scans)
- Cueing approaches, in neglect treatment, 360–363
- Cueing hierarchies. *See also* Chaining techniques, 314, 315*t*, 316–317
- Cultural variables. *See* Ethnocultural variables
- C-VIC. *See* Computer-Assisted Visual Communication system (C-VIC)
- From *Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice*, 2nd Ed., by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.

CVLT-2. *See California Verbal Learning Test—Second Edition (CVLT-2)*
 CVMT. *See Continuous Visual Memory Test (CVMT)*
 Czech speakers. *See also Non-English speakers, 173*

D

Daily Mishaps Test, 214
Dartmouth COOP Functional Assessment Charts, 290
 Databases, 7, 8*t*
 DCT. *See Discourse Comprehension Test (DCT)*
 Deblocking activities. *See also Speech perception tasks, 310–311*
 Declarative memory, 20, 21*f*, 22, 31
Delis-Kaplan Executive Function System (D-KEFS), 207, 239, 241–242
 Dementia. *See also Progressive neurological diseases; specific conditions*
 AIDS and HIV and, 93
 chemosensory impairments and, 149–150
 complicating conditions in, 152, 154
 functional outcomes of, 74, 76
 inappropriate assessment of, 227*s*, 234*s*
 overview of, 72, 73*s*
 patient interview and limitations from, 128
 prognostic factors in, 219
 psychiatric disorders screenings an, 160
 quality-of-life measures for, 293
 symptoms of, 73–76
 Dementia Outcomes Measurement Suite (DOMS), 293
Dementia Quality of Life Questionnaire (DQOL), 293
Dementia Rating Scale—Second Edition, 232, 262
 Dementia tests, 176–177*t*, 183–185, 232, 233, 239, 262
 Dementia treatment. *See also Behavioral approaches for cognitive disorders*
 CAM, 458, 460, 463–464
 communication partner training, 444–445
 general cognitive stimulation approaches, 386
 in groups, 438–439
 lack of referrals for, 299–300
 memory treatment, 371, 374
 pharmacotherapy approaches, 399*t*, 402, 408
 reality orientation to environment, 449–450
 social conventions treatment, 348
 Dementia with Lewy bodies. *See also Dementia, 74, 158, 212, 219, 399*t*, 406*
 DEMQOL, 293
 Depression
 caregiving consequences and, 143
 as a complicating condition, 158–159
 as prognostic factor, 220
 pseudodementia and, 112
 SSRIs and, 408
 tests for, 206
 Derivational morphemes, 18, 202
 Diabetes, as prognostic factor, 268*t*, 269
 Diagnosis-related groups (DRGs), 486
 Diagnostic questions, 9*s*
 From *Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice, 2nd Ed.*,
 by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.

Diagnostic reports, 144–145
 Dichotomous classification systems, 46–47
 Differential diagnosis, 472, 473, 475, 476
 Disability, 3
 Discharge recommendations, 476–477, 478
 Discounted fee-for-service model, 484
Discourse Comprehension Test (DCT), 206
 Discourse genres, 209–210, 212–213
 Discourse informativeness, 61, 71, 199
 Discourse interpretations, 62
 Discourse macrostructure, 61, 71
 Discourse processing. *See* Pragmatics and discourse processing
 Discourse samples, 191, 199, 204–205, 209–213
 Disinhibition, 75, 158, 382–383
 Disjunct markers, 441
 Disruptive behaviors. *See also* Complicating conditions, 440, 445, 450, 459, 460
 Divided attention, 20, 249
 Documentation. *See also* Diagnostic reports, 488
 DOMS. *See* Dementia Outcomes Measurement Suite (DOMS)
 Donepezil, 399*t*, 403, 406, 407
 Dopamine. *See also* Catecholamine system, 397–398
 DQOL. *See* Dementia Quality of Life Questionnaire (DQOL)
 Drawings, 57*f*, 214, 233, 250, 413–416
 DRGs. *See* Diagnosis-related groups (DRGs)
 Drug treatments. *See* Pharmacotherapy approaches
 Dual coding, 369
 Dysarthria, 128, 154, 155*t*, 156, 156*s*
Dysarthria Examination Battery, 154
 Dysphagia treatment. *See also* Swallowing function and services, 487, 490*s*

E

Ecological validity, 137, 392
 Economics. *See* Health-care economics
 Edema, in the brain, 100
 Education. *See* Caregiver education; Counseling and education; Family education; Team education
 Education, as a testing confound, 214–215, 229
 Education, as prognostic factor, 268
 EEG. *See* Electroencephalography (EEG)
 Efficacy. *See* Treatment efficacy
 Effortful learning, 374, 375
 Egocentric output, 61
 Elder Rehab program, 463
 Electroencephalography (EEG), 27*s*
 Electronic indexes, 7, 8*t*
 Ellipsis, 211
 Embolic stroke, 86–87
 Embolus, 86
 Emotion perception deficits and treatment, 349
 “Empty speech,” 38
 Encoding, 21*f*, 23–24, 31
 From *Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice*, 2nd Ed., by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.

- Encoding deficits, 58, 69–70
- Endarterectomy, 87
- Energent awareness deficit, 70
- Environmental adaptation approaches, 376–377
- Environmental agnosia, 152
- Environmental factors. *See also* Contextual factors
 acoustics, 448–449
 definition of, 4
 formal tests and effects of, 134
 hidden deficits due to, 59–60, 123, 228, 266
 ICF assessment goals and, 118, 122
 modifications to, 448–451
 MS and, 109
 neglect syndrome and, 249
 observations and, 133, 285
 Parkinson's disease and, 107
 pragmatics and discourse processing and, 341, 348–349
 principles for organizing, 450–451
 psychiatric disorders and, 159
 screenings and, 174s
 TBI attention deficits and, 68
 variability in aphasia symptoms across, 133
- Episodic memory, 21–22, 31, 69
- Error analyses, 199–201, 204–205
- Errorless learning, 373, 374–375, 391, 432
- Ethics. *See also* Clinical reasoning, 116s
- Ethnic differences. *See also* Ethnocultural variables; Racial differences, 85, 102
- Ethnocultural variables. *See also* Authentic assessment and ethnography
 AAC and, 420
 in assessments, 139s, 142–143s
 generalization and, 354
 pragmatics and discourse processing and, 340
 as a testing confound, 215, 229
 in tests, 178
- Event Drawing Task, 214
- Evidence-based practice (EBP). *See also* Functional outcomes, 6–13, 490
Examining for Aphasia—Fourth Edition, 176*t*
- Executive functioning, 24, 32–33, 222, 270, 369
- Executive functioning deficits, 44–45, 59, 70–71, 75
- Executive functioning screenings, 229
- Executive functioning tests, 207, 233, 241–243, 257–265
- Executive Function Route-Finding Task, 259
- Executive function treatment, 376–378, 379*t*, 380–386
- Exercise, 462–465
- Expanded Trail Making Test*, 248, 249
- Expression deficits. *See* Production deficits
- Expressive aphasia. *See also* Broca's aphasia, 46–47
Expressive Vocabulary Test—Second Edition, 198
- External devices. *See also* Augmentative or alternative communication (AAC); Memory aids,
 413–418, 425, 426*t*, 427–432

F

- Facebook, 443s
- “Face-saving” repair strategies, 442–443
- Falls, 95
- False starts, 200, 200*t*
- Families. *See also* Caregivers, 122, 164s, 210
- Family attitudes. *See also* Caregiver attitudes, 216*t*, 218
- Family education. *See also* Caregiver education; Counseling and education
 - in acute care, 477
 - HIPPA and, 482
 - in ICUs, 474
 - lighthouse imagery strategy, 361
 - prognosis and, 219
 - in SNFs, 478–479
- FAS test, 263
- FAVRES. *See Functional Assessment of Verbal Reasoning and Executive Strategies* (FAVRES)
- FCMs. *See Functional Communication Measures* (FCMs)
- FCP. *See Functional Communication Profile* (FCP)
- FDA-2. *See Frenchay Dysarthria Assessment—Second Edition* (FDA-2)
- Fee-for-service model, 483–484
- Figurative language, 60, 71, 76, 446*t*
- Figurative language and alternative meanings treatment, 341–345
- Fillers, 200
- FIM. *See Functional Independence Measure* (FIM)
- FLCI. *See Functional Linguistic Communication Inventory* (FLCI)
- Floor effect, 239
- Florida Affect Battery*, 192
- FLS. *See Functional Life Scale* (FLS)
- Fluency. *See* Speech fluency
- Fluency tests, 263
- Fluent aphasia, 46, 47
- Fluvoxamine, 400*t*, 408
- FMRI. *See* Functional magnetic resonance imaging (fMRI)
- Focused attention, 20, 20*t*, 62
- Focused attention tests, 248–249
- Formal test procedures, 134–143
- Fornix, 32*f*
- Forward chaining, 373–374
- Frenchay Dysarthria Assessment—Second Edition* (FDA-2), 154
- French speakers, 239, 243
- Frontal Assessment Battery*, 232
- Frontal lobe lesions, tests for, 207
- Frontal lobes
 - blood supply for, 81, 82*f*
 - Coup and contrecoup injuries in, 98
 - dopamine and, 401
 - functions of, 28*f*, 31, 32–33
 - Korsakoff’s disease and, 110
- Frontotemporal dementia. *See also* Dementia
 - aphasia and, 63–64s, 202

- diagnosing, 106–107s
- pharmacotherapy approaches for, 399t, 406, 408
- prognostic factors in, 270
- symptoms of, 73–74, 75, 76, 219
- tests for, 208, 212
- Frontotemporal lobar degeneration (FTLD)
 - complicating conditions in, 158, 159
 - definition and overview of, 105–107
 - PPA and, 52
 - screenings for, 173
 - tests for, 184, 232
- Functional Assessment of Verbal Reasoning and Executive Strategies* (FAVRES), 259
- Functional communication. *See* Assessments of activity, participation, and quality of life
- Functional Communication Measures* (FCMs), 281, 282t, 283, 286
- Functional Communication Profile* (FCP), 283–284
- Functional deficits, 488
- Functional Independence Measure* (FIM). *See also* ASHA *Functional Assessment of Communication Skills for Adults* (ASHA FACS), 280, 285
- Functional Life Scale* (FLS), 287
- Functional Linguistic Communication Inventory* (FLCI), 176t, 184
- Functional magnetic resonance imaging (fMRI), 27s
- Functional measures, 274–275, 279–286
- Functional outcomes. *See also* Cognitive outcomes and prognosis; Linguistic outcomes and prognosis; *specific cognitive-communication disorder*
 - amnesia and, 67, 69
 - anosognosia and, 59, 226
 - blast injuries and, 97
 - CAM and, 460, 461–462, 463, 464
 - caregiver assessment and, 143
 - complicating conditions and, 134
 - external devices and, 427
 - group treatment and, 434
 - ICF assessment goals and, 118
 - limb apraxia and, 157
 - making assumptions about, 118–119
 - of memory books, 430
 - neglect and, 43, 56, 226
 - psychiatric disorders and, 159
 - thorough assessments and, 116
 - vegetative state and, 66
 - vocation and, 226
- Functional tasks integration, for generalization, 366
- Functional tests, 242–243, 252, 262–263
- Funding agencies. *See also* Health-care funding models; Medicaid; Medicare; Private insurers; Third-party payers, 355

G

- Galantamine, 400t, 402, 406
- Gaming platforms, 388

- GCS. *See* Glasgow Coma Scale (GCS)
- Gender differences
 - Alzheimer's disease and, 102
 - FTLD and, 105
 - meningiomas and, 91
 - MS and, 109
 - Parkinson's disease and, 107
 - Pick's disease and, 105
 - as prognostic factors, 216*t*, 217–218, 268
 - strokes and, 85
 - TBI and, 95
- General cognitive functioning tests, 235, 236–237*t*, 238–239
- Generalization
 - of attention treatment, 364–365
 - of computer-assisted therapy programs, 353
 - external devices and, 427
 - factors to encourage, 354–355, 392, 431–432
 - of general cognitive stimulation approaches, 387
 - of linguistic stimulation treatment, 317, 319, 321, 322
 - of morphosyntactic treatment, 334, 336, 338, 342, 344
 - of neglect treatment, 360, 361
 - of phonological treatment, 307
 - of semantic treatment, 323, 326, 328
- Genres. *See* Discourse genres
- Geographic differences, 85, 109, 123*s*
- German speakers, 243
- Gestures, 41, 213, 416–418
- GI. *See* Guided imagery (GI)
- GIST. *See* Group Interactive Structure Treatment (GIST)
- Glasgow Coma Scale (GCS), 65
- Glioblastomas, 91
- Global aphasia, 48*t*, 49, 221
- Goal Management Training (GMT), 384, 385*f*
- Goal setting, planning, and problem-solving impairments treatment, 383–386
- GORT-5. *See* *Gray Oral Reading Tests—Fifth Edition* (GORT-5)
- Graphemes, 17
- Graphemic processing. *See* Orthographic processing
- Graphic displays. *See* Metaphor Training Program (MTP)
- Gray Oral Reading Tests—Fifth Edition* (GORT-5), 207
- Greek speakers, 197, 292
- Group Interactive Structure Treatment (GIST), 350
- Group treatment
 - awareness training, 380
 - as compensatory strategy, 415*f*, 416
 - conversational skills and, 347
 - in LTC settings, 479
 - overview of, 434–439
 - social conventions treatment and, 348, 349, 350
- Guided imagery (GI), 458

H

- HAND (HIV-associated neurocognitive disorders), 93
- Handicap, 3
- HD. *See* Huntington's disease (HD)
- Health-care delivery models. *See* Continuum of care
- Health-care economics, 476, 483–490
- Health-care funding models, 483–486
- Health-care providers. *See also specific professionals*, 447–448, 449, 474, 477, 478–479, 489–490
- Health-care reform. *See* Patient Protection and Affordable Care Act (2010)
- Health-care settings. *See also specific levels of care*, 116, 116s, 117, 123
- Health Insurance Portability and Accountability Act (HIPAA 1996), 482
- Health literacy, 145, 160
- Hearing loss. *See also* Acoustic environment, 148
- Hearing screenings, 148
- Helm Elicited Program for Syntax Stimulation* (HELPSS), 333–335
- HELPSS. *See Helm Elicited Program for Syntax Stimulation* (HELPSS)
- Hematomas, 88, 97, 98t
- Hemiakinesia, 57
- Hemianesthesia, 149
- Hemianopsia, 149
- Hemi-inattention. *See also* Neglect syndrome, 56–57
- Hemiparesis, 156
- Hemiplegia, 156
- Hemispatial neglect. *See also* Neglect syndrome, 56–57
- Hemispatial patching or sunglasses, 359
- Hemorrhagic strokes, 86f, 88–89
- HHRGs. *See* Home health resource groups (HHRGs)
- Hierarchy for cueing. *See* Cueing hierarchies
- Hierarchy of evidence, 6
- Hierarchy of pre-stimulation cues. *See* Contextual Constraint Treatment
- Hierarchy of syntactic constructions. *See Helm Elicited Program for Syntax Stimulation* (HELPSS)
- Higher-level language processes. *See also* Pragmatics and discourse processing, 180
- HIPAA. *See* Health Insurance Portability and Accountability Act (HIPAA 1996)
- Hippocampus, 31
- HIV, 93
- Holistic treatment. *See* Complementary and alternative medicine (CAM)
- Home health care, 118, 479–480
- Home health resource groups (HHRGs), 486
- Homonymous hemianopsia, 149
- Hopkins Verbal Learning Test–Revised*, 252
- Hospitals. *See* Health care settings; *specific levels of care*
- Human immunodeficiency virus (HIV), 93
- Humor appreciation, 60, 350
- Huntington's disease (HD)
 - complicating conditions in, 157, 158
 - lesion location for, 73s
 - overview of, 108–109, 219
 - pharmacotherapy approaches for, 400t, 405, 406

- sensory stimulation and, 460
 - tests for, 196, 206
- Hypoxic-ischemic brain injuries, 100, 101
- I
- ICD-50. *See* Sony IC Recorder (ICD-50)
- ICF. *See* International Classification of Functioning, Disability, and Health (ICF)
- ICIDH. *See* International Classification of Impairment, Disability, and Handicap (ICIDH)
- Iconic gestures, 213
- ICUs. *See* Intensive care units (ICUs)
- Ideational apraxia, 157
- Identification cards, 422
- Ideomotor apraxia, 157
- Illogical verbal output, 54
- Imagery. *See* Guided imagery (GI); Lighthouse imagery strategy; Visual imagery
- Impairment, 3
- Impulsivity. *See* Disinhibition
- Incentives, therapy, 487
- Indefinite substitutions, 39, 40*t*, 200
- Infarcts, 86
- Infections, 92–94, 100, 113
- Inferencing, 61, 63, 347
- Inflectional morphemes, 18, 202
- Informativeness. *See* Discourse informativeness
- Inhibition, 23, 24, 32, 45, 258, 261–262
- Initiation, 32, 75
- In-network providers, 484–485*s*
- Inpatient rehabilitation, 477–478
- Insurance agencies. *See* Private insurers
- Intake form, 168–170*f*
- Intellectual awareness deficit, 70
- Intelligence. *See* Premorbid intelligence
- Intensive care units (ICUs), 472–474
- Intention treatment, 392
- Interaction, 454
- Internal capsule, 29, 30*f*, 83
- International Classification of Functioning, Disability, and Health (ICF)
 - assessment goals in, 117*t*, 118, 122, 133, 144
 - assessments of activity, participation, and quality of life and, 274–275
 - CAM and, 457
 - EBP applied to, 11, 13
 - overview of, 2–6
- International Classification of Impairment, Disability, and Handicap (ICIDH), 2
- Interpreters, 142–143*s*
- Inter-rater reliability, 135, 136*t*
- Intervention. *See* *specific approaches or treatments*
- Interview formats, 132–133
- Intracranial pressure, 100
- iPads, 420, 421

iPhones, 421
 Irreversible dementia. *See also* Vascular dementia, 107, 110, 112
 Ischemic strokes. *See also* Strokes, 86–87, 89–90
 Isolation aphasia. *See* Transcortical aphasia
 Italian speakers, 292

J

Jargon, 37*t*, 39
 Joint Commission of Accreditation of Healthcare Organizations (JCAHO), 122

K

Keywords, 308–309
 Kindle Fires, 420
 Knowledge base. *See* Declarative memory
 Korean speakers, 243
 Korsakoff's disease, 110, 373

L

Labeling behavior, 199
 Labiality, 67, 158
 Lacunar stroke, 86
 Language. *See also* Bilingualism; Bilingual speakers; Linguistic processing, 14, 28–29, 30*f*
 Language disorders. *See also specific conditions*, 8*t*, 111–113
 “Language neurotransmitter,” 397–398*s*
 Language sampling. *See also* Discourse samples, 198–201, 209–213
Language Screening Test, 172
La Trobe Communication Questionnaire, 167, 174, 286
 Learning. *See* Encoding
 Left frontal lobe, 28, 31
 Left hemisphere, 28–29, 56, 401
 Left hemisphere disorders. *See also* Aphasia; Right-sided neglect
 ASHA FACS and, 281
 assessment goals in, 117*t*, 119
 complicating conditions after, 150, 153, 156–157
 prognostic factors in, 269–270
 Left parietal lobe, 29
 Left prefrontal cortex, 31
 Left-sided neglect. *See also* Neglect syndrome, 68
 Legibility. *See also* Spelling deficits treatment, 41
 Legislation, 481–482, 486–490
 Lesion locations
 assessment goals and, 117*t*, 119, 165–166
 as prognostic factors, 216*t*, 218–219, 222, 269–270
 Lesion method, 26*s*
 Letter-to-sound rules, 16*f*, 17
 Levels-of-evidence rating scales, 10
 Levodopa, 399*t*, 401
 Lewy body dementia. *See* Dementia with Lewy bodies
 Lexical ambiguity resolution, 61
 Lexical markers, 211

- Lexical Orthographic Familiarity Test*, 218
- Lexical–semantic processing, 16*f*, 17, 41, 60, 76, 194–195*t*
- Lexical–semantic processing tests, 193–201
- Lexical–semantic treatment approaches. *See also* Combined semantic and phonological treatment approaches
- brain stimulation approaches, 331–332
 - cognitive neuropsychological approaches, 322–331
 - linguistic stimulation approach, 310–314, 315*t*, 316–319, 320*t*, 321–322
- Life Participation Approach to Aphasia (LPAA). *See also* Social models, 452–453
- Lighthouse imagery strategy, 361
- Lighting, 449
- Liles Communication Test*, 212
- Limb activation training, 361–362
- Limb and head movements, as intention treatment, 392
- Limb apraxia, 41, 156–157
- Limbic system, 33
- Lindamood Phoneme Sequencing Program for Reading, Spelling, and Speech* (LiPS). *See also* *Auditory Discrimination in Depth* (ADD), 303
- Line bisection tasks, 249, 251
- Lingraphica system, 421
- Linguistic ambiguity awareness, 341–342
- Linguistic disorders assessment of body structure and function
- cognitive ability evaluation during, 266–267
 - overview of, 166–174
 - specific tests for, 185, 186–214
 - test confounds, 214–215
- Linguistic disorders treatment. *See* Activity-focused treatment; Behavioral approaches for linguistic disorders; Participation-focused treatment; Pharmacotherapy approaches
- Linguistic outcomes and prognosis, 215, 216*t*, 217–221
- Linguistic processing, 15, 16*f*, 17–18, 25, 40
- Linguistic Specific Treatment. *See* Treatment of underlying forms (TUF)
- Linguistic stimulation approaches, 300, 310–321, 333–335
- Linguistic-theory-motivated approaches, 335–338
- LiPS. *See* *Lindamood Phoneme Sequencing Program for Reading, Spelling, and Speech* (LiPS)
- Literacy. *See* Health literacy; Reading
- Literacy, as a testing confound, 215
- Literacy problems. *See* Reading deficits treatment
- Literal paraphasias. *See* Phonemic or literal paraphasias
- Living With Aphasia: Framework for Outcome Measurement* (A-FROM), 275*s*
- Location Learning Test*, 257
- Logopenic progressive aphasia, 52, 53*t*
- Long-term care (LTC) settings, 117, 117*t*, 282, 479
- Long-term memory, 20–22, 23–24, 31–32, 44
- LPAA. *See* Life Participation Approach to Aphasia (LPAA)
- LTC. *See* Long-term care (LTC) settings

M

- Magnetic resonance imaging (MRI), 26*s*, 332
- Magnetoencephalography (MEG), 27*s*
- Maintenance. *See* Generalization

- Malignant brain tumors, 91, 92
- Managed care models, 484–486
- Mapping therapy, 335–336, 391
- Marketing of services, 489–490
- MAST. *See* *Mississippi Aphasia Screening Test (MAST)*
- Maze completion tests, 258
- MCST-A. *See* *Multimodal Communication Screening Task for Persons With Aphasia (MCST-A)*
- MDS. *See* Minimum Data Set (MDS)
- Medicaid. *See also* Centers for Medicare and Medicaid Services (CMS), 281, 439, 481–482, 484
- Medical factors, in prognosis, 218–220
- Medical professionals. *See also specific type of professional*, 447–448
- Medical records review, 124–126
- Medicare. *See also* Centers for Medicare and Medicaid Services (CMS)
- case rate system in, 486
 - documentation and, 488
 - fee-for-service model and, 484
 - group treatment and, 436–437s, 439
 - MDS and, 281
 - overview of, 481
- Medications. *See also* Pharmacotherapy approaches, 216t, 269
- Meditation, 458
- MEG. *See* Magnetoencephalography (MEG)
- Melodic Intonation Therapy (MIT), 319–321
- Memantine, 400t, 408
- Memory, 20–24, 31–32
- Memory aids. *See also* External devices, 375–376, 377
- Memory books, 428–430
- Memory deficits
- AAC and, 420
 - anterograde amnesia and, 69
 - with aphasia, 43–44
 - in dementia, 74–75
 - in RHD, 58
 - in TBI, 69–70, 71
- Memory for Intentions Test (MIST)*, 255–256
- Memory retrieval, 21f, 23–24, 31
- Memory tests, 233, 240–241, 252–257
- Memory treatment, 367–376
- Men. *See* Gender differences
- Meningiomas, 91
- Mental Slowness Questionnaire, 229
- Mental-state inferencing, 32
- Meta-cognitive abilities, 24
- Metacognitive training, 358
- Metalinguistic awareness. *See also* Linguistic ambiguity awareness; Topic coherence and cohesion, 340–341
- Metalinguistic comments, 200t
- Metaphor Training Program (MTP), 343–344
- Metastatic brain tumors, 91
- Methylphenidate, 399t, 404
- Micrographia, 107, 108f
- From *Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice*, 2nd Ed., by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.

- Mild cognitive impairment (MCI), 72, 364, 374, 458
- Mild language impairments tests, 190
- Mini Inventory of Right Brain Injury* (MIRBI), 180
- Mini Inventory of Right Brain Injury—Second Edition* (MIRBI-II), 140, 176*t*, 180
- Minimally conscious state, 66–67
- Mini-Mental State Examination* (MMSE), 231, 233, 234*s*
- Mini-Mental State Examination—Second Edition* (MMSE-2), 227*s*, 231, 265
- Minimum Data Set (MDS), 281–283, 486
- MIRBI. *See Mini Inventory of Right Brain Injury* (MIRBI)
- MIRBI-II. *See Mini Inventory of Right Brain Injury—Second Edition* (MIRBI-II)
- Mississippi Aphasia Screening Test* (MAST), 173
- MIST. *See Memory for Intentions Test* (MIST)
- MIT. *See Melodic Intonation Therapy* (MIT)
- MMSE. *See Mini-Mental State Examination* (MMSE)
- MMSE-2. *See Mini-Mental State Examination—Second Edition* (MMSE-2)
- Mnemonic strategies, 368–369
- Modafinil, 400*t*, 408
- Modifications. *See also* Accommodations; Compensatory strategies
 - environmental adaptation approaches, 376–377
 - of environment and task for neglect treatment, 358–360
 - of physical environment, 448–451
 - qualitative information from, 142
 - to social environment, 440–448
 - in stimulus and test administration, 142
 - theoretical framework and treatment, 301*s*
 - of treatment protocols, 319*s*
- Modified Wisconsin Card Sorting Test* (M-WCST), 260
- Monocular eye patching, 359
- MOR. *See Multiple Oral Rereading* (MOR)
- Morphemes, 18
- Morphosyntactic processing, 17–18, 38, 41, 76
- Morphosyntactic processing tests, 202–205
- Morphosyntactic treatment approaches, 333–338
- Mosquitoes, 93–94*s*
- Moss Attention Rating Scale, 229
- Motivation, 32, 216*t*, 218
- Motor extinction or neglect, 57
- Motoric impairments screenings, 153–154, 156–158
- MRI. *See Magnetic resonance imaging* (MRI)
- MTP. *See Metaphor Training Program* (MTP)
- Multicomponent Intervention Program, 387
- Multidisciplinary involvement. *See also* Team approach, 5
- Multilingual aphasia, 51–52
- Multilingual Aphasia Examination*, 178
- Multilingualism. *See also* Bilingual speakers, 338–339*s*
- Multimodal Communication Screening Task for Persons With Aphasia* (MCST-A), 419
- Multimodality communication approaches, 415*f*, 441–442
- Multiple Oral Rereading (MOR), 324
- Multiple sclerosis (MS)
 - lesion location for, 73*s*
 - meditation and, 458
- From *Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice*, 2nd Ed., by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.

- pharmacotherapy approaches, 399*t*, 400*t*
- prevalence of, 109
- reversible dementia in, 112
- symptoms of, 109–110
- tests for, 206, 243

M-WCST. *See Modified Wisconsin Card Sorting Test (M-WCST)*

N

NAB. *See Neuropsychological Assessment Battery (NAB)*

NAB Mazes Test, 258

NAB Naming Test, 198

Naming. *See Anomia*

Naming errors, 54

Narrative rules, 18

National Aphasia Association, 422

National Center for Complementary and Alternative Medicine (NCCAM), 457

National Head Injury Foundation, 94

National Institutes of Health (NIH), 94*s*

National Outcomes Measurement System (NOMS), 281, 282*t*, 283

Native language, RHD and, 60

Naturalistic Action Test, 157

Naturalistic tests, 242–243, 252, 262–263

N-back tasks, 254, 255*f*

NCCAM. *See National Center for Complementary and Alternative Medicine (NCCAM)*

Neck stimulation, 363

Neglect-alert device, 361

Neglect dysgraphia, 58

Neglect dyslexia, 58

Neglect syndrome

- AAC and, 419

- dementia and, 74

- environmental factors and, 249

- overview of, 54, 56–58

- as prognostic factor, 222, 269, 270

- right-sided neglect, 43, 68

- TBI and, 68

- TENS and, 462

Neglect tests, 249–252

Neglect treatment, 358–363, 424

Neologisms, 37*t*, 39, 40*t*, 50, 200

Neoplasms. *See Brain tumors*

Neuroanatomy

- in aphasia, 47, 48*t*, 49, 50

- of cognition, 30–33

- functional outcomes and, 71–72

- of language, 28–29, 30*f*

Neurobehavioral Functioning Inventory, 167

Neurogenic stuttering, 156*s*

Neuroleptic medications, 400*t*, 407–408

Neurological examination procedures, 129*t*

Neurological incidences, xi
 Neurologists, 472
 Neuropage system, 427, 428
 Neuroprotective agents, 90
Neuropsychological Assessment Battery (NAB), 176*t*, 235, 238
 Neuropsychologists, 120*t*, 121*s*, 122, 152, 226, 366*s*
 Neurotransmitters, 396–398
 NIH. *See* National Institutes of Health (NIH)
 NOMS. *See* *National Outcomes Measurement System* (NOMS)
 Noncanonical word order. *See also* Mapping therapy, 18, 203
 Nondeclarative memories, 21*f*, 22, 70
 Non-English speakers. *See also* *specific language speaker*, 142–143*s*, 178, 233, 265
 Nonfluent aphasia, 46, 47
 Nonfluent progressive aphasia, 202
 Nonreversible dementia, 109
 Non-standardized assessment procedures, 476*s*
 Nonverbal cues difficulty, 54, 60, 61, 150
 Nonverbal memory tests, 256–257
 Nonword syllable same-or-different judgment, 302
 Noradrenalin. *See also* Catecholamine system, 397–398*s*
 Norepinephrine, 398
 No responses, 200
 Nurses. *See also* Health-care providers, 474*s*

O

OASIS. *See* Outcome and Assessment Information Set (OASIS)
Object Sorting Test, 260
 Observations

- in assessments, 122, 133–134, 228–229
- for complicating conditions, 164*s*
- formal apraxia tests and, 158
- of functional communication, 285
- of participation, 288
- pharmacotherapy approaches and, 396, 405*s*
- during testing, 167, 171

 Occipital lobes, 82*f*, 83
 Occupational therapists, 120*t*, 122, 152, 226, 366*s*
 OCEBM. *See* Oxford Centre for Evidence-Based Medicine (OCEBM)
 Office of Technology Assessment (OTA), 9, 10
 OneQ, 291
 Open class words, 202
 Open head injuries. *See also* Traumatic brain injuries (TBI), 96, 97
 Optokinetic stimulation, 359
Oral and Written Language Scales—Second Edition (OWLS-2), 176*t*, 204
Oral Reading for Language in Aphasia (ORLA), 330–331
 Organization deficits, 24, 45, 61
 Organization tests, 258, 259–260
 Orientation level. *See also* Reality orientation to environment, 128, 230*t*
Orientation Log, 232
 Orthographic input and output lexicons and buffers, 16*f*, 17

Orthographic processing, 16*f*, 17
 Orthographic processing tests, 192–193
 Orthographic treatment approaches, 307–310, 311*t*
 OTA. *See* Office of Technology Assessment (OTA)
 Outcome and Assessment Information Set (OASIS), 486
 Outcome evaluations, 11
 Outcomes. *See* Cognitive outcomes and prognosis; Functional outcomes; Linguistic outcomes and prognosis; Program evaluations
 Out-of-network providers, 484*s*
 Outpatient care, 117, 118, 480–481
 Output paucity or excess, 61
 Overt memory strategies, 424
 OWLS-2. *See* *Oral and Written Language Scales—Second Edition* (OWLS-2)
 Oxford Centre for Evidence-Based Medicine (OCEBM), 10, 13*f*

P

PACE. *See* *Promoting Aphasics' Communicative Effectiveness* (PACE)
Paced Auditory Serial Addition Test, 243
 Pacing strategies, 424
 Paging system. *See* Neuropage system
 PALPA. *See* *Psycholinguistic Assessments of Language Processing in Aphasia* (PALPA)
 Pantomime, 417–418
 Paragrammatism, 37*t*, 38
 Paraneoplastic syndromes, 92
 Paraphasias, 38–39, 40*t*, 50
 Parietal lobes, 81, 82*f*
 Parkinson's disease (PD)
 acupuncture and, 462
 complicating conditions in, 152, 156*s*, 157, 158
 lesion location for, 73*s*
 pharmacotherapy approaches, 399*t*, 400*t*, 406
 prevalence of, 107
 prognostic factors in, 269
 symptoms of, 74, 75, 76, 108*f*, 219
 TBI incidence and, 95
 tests for, 184, 206, 232
Parkinson's Disease—Cognitive Rating Scale, 232
 Participation-focused treatment. *See also* Activity-focused treatment, 451–457
 Participation measures, 275, 286–288
 Patching. *See* Monocular eye patching
 Patient and caregiver interviews, 126, 128, 129, 131–133
 Patient education. *See also* Counseling and education
 in acute care, 477
 assessment results sharing and, 145
 awareness training, 377–378, 379*t*, 380
 on memory books, 428–430
 on strategy and external device training, 431–432
 on topic coherence and cohesion treatment, 347
 on treatment purposes, 301*s*
 Patient intake form, 168–170*f*
 Patient Protection and Affordable Care Act (2010), 482, 486, 489
 From *Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice*, 2nd Ed., by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.

- Patients, as part of team approach, 122
- PCAD. *See* Personal Communication Assistant for Dysphasic People (PCAD)
- PD. *See* Parkinson's disease (PD)
- PECOT approach, 7
- Pediatric Test of Brain Injury* (PTBI), 176*t*, 182
- Perception, 14–15
- Perceptual deficits, 54, 55–56*t*, 73–74
- Perceptual deficits screenings, 150, 151*t*, 152
- Per diem funding, 485
- Permanent vegetative state, 66
- Perseveration, 75, 381–382, 385
- Persistent vegetative state (PVS), 66
- Personal Communication Assistant for Dysphasic People (PCAD), 421
- Personal factors, 4
- Personal information cards, 422
- Personalized cues, 314
- PET. *See* Positron emission tomography (PET)
- Pharmacotherapy approaches, 395–407
- Philadelphia Brief Assessment of Cognition*, 232
- Phoneme discrimination, 302
- Phoneme-grapheme matching, 302
- Phonemes, 15
- Phonemically related paraphasias, 200
- Phonemic or literal paraphasias, 37*t*, 39, 40*t*, 199–200
- Phonetic perception tests, 191
- Phonological input and output lexicons and buffers, 15, 16*f*, 17
- Phonological processing, 15, 16*f*, 17
- Phonological processing tests, 190–193
- Phonological treatment approaches. *See also* Combined semantic and phonological treatment approaches, 302–307, 316*f*, 329, 330
- Phonology tests, 190–192
- Photocopy task, 262
- Physicians. *See* Health-care providers; Neurologists
- Physostigmine, 400*t*, 402
- Pick's disease, 52, 73*s*, 105
- Pictionary, 413, 414
- Piracetam, 400*t*, 402, 406
- Pitch analysis system, 306
- Pitch discrimination deficits, 54, 55*t*, 150
- Planning deficits, 24, 32, 45, 75
- Planning deficits treatment, 385–386
- Planning tests, 258–259
- PMR. *See* Progressive muscle relaxation (PMR)
- Porch Index of Communicative Ability*, 173, 176*t*
- Porteus Maze Test*, 258
- Positive communication skill training. *See under* Communication partners
- Positron emission tomography (PET), 27*s*
- Post-traumatic amnesia (PTA), 67, 68
- PPA. *See* Primary progressive aphasia (PPA)
- PPS. *See* Prospective payment systems (PPS)
- Practice, generalization and, 392
- From *Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice*, 2nd Ed., by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.

- Practice-based evidence, 11
- Pragmatic Protocol, 211–212
- Pragmatics and discourse impairment treatment, 128, 339–351
- Pragmatics and discourse processing, 18, 60–63, 70, 71, 215
- Pragmatics and discourse tests, 190, 205–213
- Pre-authorization of services, 484
- Predictive validity, 136*t*, 137
- Pre-existing conditions. *See* Complicating conditions
- Preferred provider models, 484–486
- Prefrontal cortex, 31
- Premorbid abilities. *See also* Case histories; Patient and caregiver interviews, 119, 216*t*, 218, 268, 269
- Premorbid intelligence, 218, 268
- Preprocessed evidence, 11
- Presbycusis, 148
- Prevention and wellness activities, 470–472*s*
- Primary brain damage, 97–98, 97–99
- Primary brain tumors, 91
- Primary care, 470
- Primary progressive aphasia (PPA), 39*f*, 52, 53*t*
- Prism lenses, 359
- Private insurers. *See also* Third-party payers, 116, 299–300, 481
- Problem solving, 24, 32, 45, 70
- Problem-solving tests, 258, 262–263
- Procedural memory, 21*f*, 22, 31, 70, 74
- Process measures, 279–280
- Production deficits, 305–307, 313–322, 324–328, 330, 344–345
- Productivity targets, 486
- Professional guidelines, for assessment procedures, 120–121
- Prognostic factors. *See also* Screenings
 - in acute care, 477
 - for cognitive outcomes, 221–222, 267–270
 - for linguistic outcomes, 175, 215, 216*t*, 217–221
- Program evaluations, 279–283
- Progressive muscle relaxation (PMR), 458
- Progressive neurological diseases. *See also* Dementia; *specific condition*
 - complicating conditions in, 156*s*, 157, 158
 - diagnosing, 106–107*s*
 - overview of, 101–102
 - prognostic factors in, 219, 270
 - tests for, 232
- Progressive nonfluent aphasia, 52, 53*t*, 105
- Progressive supranuclear palsy, 73*s*
- Promoting Aphasics' Communicative Effectiveness* (PACE), 212, 432–436
- PROMPT (Prospective Memory Process Training). *See also* Spaced retrieval, 370–371
- Propopagnosia, 73, 152
- Prosody treatment, 304–307, 446*t*
- Prosopagnosia, 55*t*, 73, 152
- Prospective memories, 21
- Prospective Memory Process Training. *See* PROMPT (Prospective Memory Process Training)
- Prospective payment systems (PPS), 485

Proxemics, inappropriate, 54
 Proxy ratings, 163
 Pseudodementia, 111, 112
 Psychiatric disorders screenings, 158–160, 161–162*t*, 163
 Psychiatric illnesses, 95, 220, 269
 Psychiatric well-being measures, 161–162*t*
Psycholinguistic Assessments of Language Processing in Aphasia (PALPA), 191, 193, 201, 202, 203, 204
 Psychologists. *See also* Neuropsychologists, 121, 226
 Psychometric properties and considerations, 135–138
 PTA. *See* Post-traumatic amnesia (PTA)
 PTBI. *See* *Pediatric Test of Brain Injury (PTBI)*
 Pure agraphia, 51
 Pure alexia, 51
 Pure aphasia, 51
 Pure word deafness, 51, 150
 Putamen, 30*f*, 33, 109
Putney Auditory Comprehension Screening Test, 196
 PVS. *See* Persistent vegetative state (PVS)
Pyramids and Palm Trees, 195

Q

QOL-AD. *See* *Quality of Life in Alzheimer's Disease (QOL-AD)*
 QOLIBRI. *See* *Quality of Life After Brain Injury (QOLIBRI)*
 Qualitative information, in tests, 121*s*, 141–142
 Quality assurance. *See also* Program evaluations, 487, 488–489
Quality of Communication Life Scale (ASHA QCL), 293
Quality of Life After Brain Injury (QOLIBRI), 292
Quality of Life in Alzheimer's Disease (QOL-AD), 293
 Quality-of-life measures, 275, 288–294
 Question-framing. *See* PECOT approach
Quick Assessment for Apraxia of Speech, 153
Quick Assessment for Dysarthria, 154

R

Racial differences. *See also* Ethnic differences; Ethnocultural variables, 85, 109
 Random paraphasias, 39, 40*t*, 200
Rapid Assessment of Problem Solving, 262
Raven's Progressive Matrices, 262
 RBANS. *See* *Repeatable Battery for the Assessment of Neuropsychological Status Update (RBANS)*
 RBMT-III. *See* *Rivermead Behavioral Memory Test (RBMT-III)*
 RCBA-2. *See* *Reading Comprehension Battery for Aphasia—Second Edition (RCBA-2)*
 Reading, 17, 250
Reading Comprehension Battery for Aphasia—Second Edition (RCBA-2), 193, 195–196, 207
 Reading deficits treatment. *See also* *Auditory Discrimination in Depth (ADD)*, 307–308, 324, 346, 443*s*
 Reading tests, 191, 192–193, 207
 Reality orientation groups, 437–438
 Reality orientation to environment, 449–450
 Real world tests. *See also* *Memory for Intentions Test (MIST)*; Non-standardized assessment procedures, 242–243, 252, 262–263
 From *Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice*, 2nd Ed., by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.

- Reasoning. *See also* Clinical reasoning, 32, 45
- Reauditorization, 312
- Recall, recognition versus, 23
- Receptive aphasia. *See also* Wernicke's aphasia, 46–47
- Recognition, recall versus, 23
- Reference markers, 210–211
- Referrals
 - acquisition of, 123–124
 - for caregivers, 143
 - clinical competency to advocate for, 299–300
 - counseling and education and, 466
 - marketing and, 490
 - sources of, 470, 472, 473, 475
- Rehabilitation, in acute care, 475, 477
- Rehabilitation Act (1973), 482
- Rehabilitation settings. *See also* Inpatient rehabilitation; Long-term care (LTC) settings; Outpatient care; Skilled nursing facilities (SNFs), 117
- Reimbursement issues. *See also* Health-care funding models, 116s, 439, 490
- Relational words, 202
- Relaxation therapy, 457–459
- Relevance of information. *See* Discourse informativeness; Topic coherence and cohesion; Topic management
- Reliability, in formal tests. *See also specific tests*, 135–136
- Remediation of body structure and function. *See* Behavioral approaches for cognitive disorders; Behavioral approaches for linguistic disorders; Pharmacotherapy approaches
- Remembering. *See* Memory retrieval; Word retrieval
- Reminiscence activities, 436
- Repair strategies, 415, 433, 442–443
- Repeatable Battery for the Assessment of Neuropsychological Status Update* (RBANS), 176t, 185
- Repetitions. *See also* Perseveration, 40, 49, 50, 200
- Repetition tasks, 313–314
- Repetitive transcranial magnetic stimulation (rTMS), 331–332, 362s
- Reporter bias, 133, 229, 264–265
- Research funding, 94s
- Resources. *See* Books; Community resources; Support groups
- Resource utilization groups (RUGs), 486
- Response Elaboration Training (RET), 318
- Restorative versus adaptive treatment, 478, 479, 480
- RET. *See* Response Elaboration Training (RET)
- Retrieval. *See* Memory retrieval; Word retrieval
- Retrograde amnesia, 69
- Retrograde memories, 22
- Retrospective confidence judgments, 265
- Reversible dementia, 111–112
- Revised Token Test* (RTT), 196, 203
- Rey-Osterrieth Complex Figure Test*, 256
- Rey's Visual Design Learning Test* (RVDLT), 256
- RHD. *See* Right hemisphere disorders (RHD)
- RIC Evaluation of Communication Problems in Right Hemisphere Dysfunction—Revised*, 177t
- Right frontal lobe, 31
- Right hemisphere, 30–31, 32f

- Right hemisphere disorders (RHD)
- assessment goals in, 117*t*, 119
 - complicating conditions after, 150, 152, 157
 - crossed aphasia, 51
 - deficits associated with, 55–63
 - functional measures for, 284
 - functional outcomes of, 58, 59, 226
 - overview of, 52–54
 - patient interview and limitations from, 128
 - prevalence of, 53, 56, 59
 - prognostic factors in, 220, 269
 - psychiatric disorders screenings an, 160
 - TBI as, 68
- Right hemisphere disorder tests. *See also* Nonverbal memory tests
- dementia tests versus, 183
 - overview of, 176–177*t*, 180–181, 185, 206, 212
 - supplementary test use in, 190
- Right hemisphere disorder treatment
- APT, 364
 - CAM, 462, 464
 - communication partner training, 445–447
 - in groups, 437–438
 - pharmacotherapy approaches, 399*t*, 406
 - pragmatics and discourse impairment treatment, 341
 - pragmatics and discourse-level impairment treatment, 342, 344, 348
 - suprasegmental impairments treatment, 304–307
- Right Hemisphere Language Battery—Second Edition*, 177*t*
- Right posterior parietal cortex, 31
- Right prefrontal cortex, 31
- Right-sided neglect. *See also* Neglect syndrome, 43, 68
- RIPA. *See* *Ross Information Processing Assessment* (RIPA)
- RIPA-2, 238
- RIPA-Geriatric:2 (RIPA-G:2), 238
- Ritalin, 399*t*, 404
- Rivastigmine, 400*t*, 406
- Rivermead Behavioral Memory Test* (RBMT-III), 240–241
- Role playing, 340, 349, 350, 378, 436
- Ross Information Processing Assessment* (RIPA), 238
- Rote rehearsal, 369
- rTMS. *See* Repetitive transcranial magnetic stimulation (rTMS)
- rtPA (recombinant tissue plasminogen activator), 89–90, 472–473
- RTT. *See* *Revised Token Test* (RTT)
- Ruff Figural Fluency Test* (RFFT), 263–264
- RUGs. *See* Resource utilization groups (RUGs)
- RVDLT. *See* *Rey’s Visual Design Learning Test* (RVDLT)

S

- SADQH. *See* *Stroke Aphasic Depression Questionnaire* (SADQH)
- SADQH-10, 163
- SADS. *See* *Stroke and Aphasia Depression Scale* (SADS)
- SAQOL-39. *See* *Stroke and Aphasia Quality of Life Scale–39* (SAQOL-39)
- From *Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice*, 2nd Ed., by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.

- Satisfaction With Life Scale* (SWLS), 290–291
- SCA. *See* Supported Conversation for Adults With Aphasia (SCA)
- Scales of Cognitive and Communicative Ability for Neurorehabilitation* (SCCAN), 177*t*, 185
- Scales of Cognitive Assessment for Traumatic Brain Injury* (SCATBI), 182
- SCAN-3 *Tests for Auditory Processing Disorders in Adolescents and Adults*, 150, 151*t*
- SCATBI. *See* *Scales of Cognitive Assessment for Traumatic Brain Injury* (SCATBI)
- SCCAN. *See* *Scales of Cognitive and Communicative Ability for Neurorehabilitation* (SCCAN)
- ScreeLing, 173
- Screenings
- for caregivers, 143
 - case histories and observations as, 124
 - cognitive disorders and, 229–234
 - developing one's own, 171–172
 - inappropriate use of, 234
 - linguistic disorders and, 171–174, 178
 - in LTC settings, 479
 - for motoric deficits, 153–154, 155*t*, 156–158
 - for perceptual deficits, 150, 151*t*, 152
 - precautions in using, 171, 172, 173, 174*s*
 - for psychiatric disorders, 158–160, 161–162*t*, 163
 - for sensory deficits, 148–150
 - SLPAs and, 487
- Scripts. *See* Conversational script training
- Secondary brain damage, 100
- Secondary care, 472
- SEE. *See* Signed Exact English (SEE)
- Segmental impairments treatment, 302–304
- Segmental subsystem, 15, 190–191
- Selective attention, 20, 20*t*
- Selective attention tests, 248–249
- Selective serotonin reuptake inhibitors (SSRIs), 400*t*, 407, 408
- Self-advocacy, 379
- Self-awareness, 32, 222, 270
- Self-Awareness of Deficits Interview, 264
- Self-cue approach, 385–386, 424
- Self-monitoring. *See also* Awareness training, 24, 45, 128, 222
- Self-monitoring tests, 258, 263–265
- Self-regulation. *See also* Meta-cognitive abilities, 32
- Semantic dementia, 52, 53*t*
- Semantic elaboration, 369
- Semantic Feature Analysis (SFA). *See also* Verb Network Strengthening Treatment (VNeST), 325–326
- Semantic memory, 21–22, 31
- Semantic paraphasias, 37*t*, 39, 40*t*, 200, 200*t*
- Semantic processing. *See* Lexical–semantic processing
- Semantic treatment approaches. *See also* Combined semantic and phonological treatment approaches, 322–331
- Senior centers, 457
- Sensitivity, in psychometrics, 137
- Sensorimotor issues, gestures and, 41
- Sensory deficits screenings, 148–150
- From *Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice*, 2nd Ed., by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.

- Sensory deprivation, 459
- Sensory extinction to simultaneous stimulation, 57
- Sensory stimulation, 459–461
- Sentactics, 338
- Sentence Production Program for Aphasia (SPPA)*, 333–335
- Sentence repetition tasks, 390
- SentenceShaper, 420
- Serial lesion effect, 91–92s
- Serotonin, 398s
- Sertraline, 400t, 408
- Severe Impairment Battery (SIB)*, 177t, 184–185, 238–239
- Short-term memory, 21f, 22, 40
- SIB. *See Severe Impairment Battery (SIB)*
- Sickness Impact Profile (SIP)*, 289–290, 291
- Signed Exact English (SEE), 416
- Sign languages. *See also Gestures; Pantomime*, 213, 416–417
- Silent pauses, 200, 200t
- Singing. *See Melodic Intonation Therapy (MIT)*
- Single photon emission computed tomography (SPECT), 27s
- SIP. *See Sickness Impact Profile (SIP)*
- SIS. *See Stroke Impact Scale (SIS)*
- Skilled nursing facilities (SNFs), 478–479, 486
- SLP assistants (SLPAs), 487
- SmallTalk, 421
- Smartphones, 420, 421
- SNFs. *See Skilled nursing facilities (SNFs)*
- Snoezelen, 459–460
- Social activity, as prognostic factor, 269
- Social cognition, 62–63
- Social conventions treatment, 348–351
- Social Language Development Test–Adolescent*, 209
- Social models. *See also Life Participation Approach to Aphasia (LPAA)*, 453–454
- Social skills intervention groups, 350–351
- Social workers, 486
- Socioeconomic status, 95
- Software and applications, as treatment activities, 350–354, 363, 384, 388, 389t
- Soldiers. *See also Blast injuries; Veterans*, 94
- Somatosensory screenings, 149
- Sony IC Recorder (ICD-50), 428
- Sound-to-letter rules, 16f, 17
- Spaced retrieval. *See also PROMPT (Prospective Memory Process Training)*, 371, 372t, 375, 391
- Spanish speakers. *See also Non-English speakers*
 quality-of-life measures for, 292
 screenings for, 173
 tests for, 178, 185, 197, 243, 265
- Span tasks, 253
- Specificity, in psychometrics, 137
- SPECT. *See Single photon emission computed tomography (SPECT)*
- Speech acts, 211–212
- Speech discrimination treatments, 302
- Speech fluency, 37–38, 39f, 46
 From *Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice*, 2nd Ed.,
 by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.

- Speech perception tasks. *See also* Deblocking activities, 313
- Speech-to-text capability, 420
- Spelling deficits treatment. *See also* *Auditory Discrimination in Depth* (ADD), 308–310, 311*t*
- Spouses. *See* Caregivers
- SPPA. *See* *Sentence Production Program for Aphasia* (SPPA)
- SS-QOL. *See* *Stroke-Specific Quality of Life Scale* (SS-QOL)
- SSRIs. *See* Selective serotonin reuptake inhibitors (SSRIs)
- Standardization, in formal tests, 137–138
- Standardized tests. *See* Formal test procedures; Tests; *specific tests*
- Stereotypy, 39, 40*t*
- Stimulability, as prognostic factor, 221
- Story retelling tasks, 255, 347
- Strategic learning, 69, 369
- Strategy training, 365, 367, 368–370, 375, 424–425, 431–432
- Stroke and Aphasia Depression Scale* (SADS), 163
- Stroke and Aphasia Quality of Life Scale–39* (SAQOL-39), 292
- Stroke Aphasic Depression Questionnaire* (SADQH), 163
- Stroke belt, 85
- Stroke Impact Scale* (SIS), 287
- Strokes. *See also* Aphasia; Cerebral vascular system; Vascular dementia
 - causes of, 86*f*
 - complicating conditions after, 149, 156*s*
 - functional outcomes of, 226
 - overview of, 80
 - participation measures for, 287
 - prevalence of, 80
 - prognostic factors in, 219, 222, 270
 - quality-of-life measures for, 292
 - risk factors in, 84–85, 87
 - sensory stimulation and, 460–461
 - types of, 85–89
- Stroke-Specific Quality of Life Scale* (SS-QOL), 292
- Stroke support groups, 455, 456*t*
- Stroke survival, 89
- Stroke treatment. *See also* Aphasia treatment; Right hemisphere disorder treatment, 89–90, 373
- Stroop tasks, 261
- Study designs, evidence quality and, 10
- Stuttering, 156*s*
- Subcortical aphasia, 50–51
- Subcortical brain structures, 30*f*
- Subcortical dementia, 73*s*
- Substance abuse, 95, 110, 111, 143
- Substantive words, 202
- Superior longitudinal fasciculus, 29
- Supported Conversation for Adults With Aphasia (SCA), 443–444, 454
- Support groups, 434, 455, 456*t*, 457
- Supporting Partners of People With Aphasia in Relationships and Conversation*, 210
- Support levels, as prognostic factors. *See also* Caregiver attitudes, 269
- Suppression (SUP), 342
- Supramarginal gyrus, 28–29
- Suprasegmental impairments treatment, 304–307

Suprasegmental subsystem, 15, 190, 192
 Sustained attention, 20, 31, 62
 Sustained attention tests, 248
 Swallowing function and services, 473, 479, 489s
 SWLS. *See Satisfaction With Life Scale (SWLS)*
 Symbols, 14
 Syntactic processing. *See Morphosyntactic processing*
 Syntax, 18, 38

T

Tactile-kinesthetic treatment, for reading deficits, 307–308
 TAP. *See Treatment for Aphasic Perseveration (TAP)*
 TASIT. *See The Awareness of Social Interference Test–Revised (TASIT)*
Tasks of Executive Control, 261–262
 tDCS. *See Transcranial direct current stimulation (tDCS)*
 TEA. *See Test of Everyday Attention (TEA)*
 Teachers, 226
 Team approach, 119–123, 226, 366s, 478, 480
 Team education, 123–124
Telephone Interview for Cognitive Status (TICS), 231–232
 Telephones. *See iPhones*
 Telephone Test, 253
 Temporal lobes

- acetylcholine and, 402
- Alzheimer’s disease and, 103
- blood supply for, 81, 82f, 83
- Coup and contrecoup injuries in, 98
- functions of, 31, 32f

 TENS. *See Transcutaneous electrical nerve stimulation (TENS)*
 Tertiary care, 472
 Test confounds. *See also Complicating conditions*, 214–215, 228–229, 265–266, 274
Test for Reception of Grammar–Second Edition, 203
Test of Adolescent and Adult Language–Fourth Edition (TOAL-4), 182–183
Test of Adolescent and Adult Word-Finding, 204
Test of Everyday Attention (TEA), 239–240, 249
Test of Language Competence–Expanded Edition (TLC-E), 206
Test of Nonverbal Intelligence–Fourth Edition (TONI-4), 262
Test of Oral and Limb Apraxia, 157
Test of Pragmatic Language–Second Edition (TOPL-2), 209
Test of Problem Solving–Adolescent: Second Edition, 262
Test of Silent Reading Efficiency and Comprehension, 207
Test of Upper Limb Apraxia, 213
Test of Variables of Attention–8, 248
Test of Verbal Conceptualization and Fluency (TVCF), 263
Test of Visual Field Attention, 251
Test of Word Reading Efficiency–Second Edition, 192–193, 196
Test of Written Language–Fourth Edition (TOWL-4), 208–209
 Test-retest reliability, 136, 136t
 Tests. *See also specific tests*

- advantages to using, 140
- language sampling in, 198–201

 From *Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice*, 2nd Ed., by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.

- precautions in using, 140–141, 191, 193, 212, 241, 257–258
 - qualitative considerations in, 141–142
 - reliability and validity in, 135–137
 - selection of, 140–141
 - Text messaging, 420, 428
 - Text-to-speech capability, 420, 428
 - Thalamus
 - blood supply for, 83
 - functions of, 29, 30, 30*f*, 31, 33
 - Korsakoff’s disease and, 110
 - The Awareness of Social Interference Test–Revised* (TASIT), 207–208
 - Theme identification, 61
 - Theory of Mind, 62–63
 - Therapeutic hypothermia, 90
 - Therapeutic nihilism, 123
 - Therapy caps. *See* Caps or limits
 - The WORD Test–Second Edition: Adolescent* (TWT), 198
 - Third-party payers. *See also* Private insurers; Reimbursement issues, 281, 439, 483–484, 486
 - Thrombosis, 86, 87
 - Thrombotic strokes, 86–87
 - TICS. *See Telephone Interview for Cognitive Status* (TICS)
 - Tinnitus, 148
 - TLC-E. *See Test of Language Competence–Expanded Edition* (TLC-E)
 - TOAL-4. *See Test of Adolescent and Adult Language–Fourth Edition* (TOAL-4)
 - TOL:RV. *See Tower of London DX: Research Version* (TOL:RV)
 - TONI-4. *See Test of Nonverbal Intelligence–Fourth Edition* (TONI-4)
 - Topic coherence and cohesion, 345–347
 - Topic management, 62, 71, 76, 446*t*
 - TOPL-2. *See Test of Pragmatic Language–Second Edition* (TOPL-2)
 - TouchSpeak, 421
 - Tower of London DX: Research Version* (TOL:RV), 258–259
 - Tower tests, 258–259
 - TOWL-4. *See Test of Written Language–Fourth Edition* (TOWL-4)
 - Tracine, 399*t*, 406
 - Trail Making Test*, 248–249, 262, 263
 - Transaction, 454
 - Transcortical aphasia, 48*t*, 49, 50
 - Transcranial direct current stimulation (tDCS), 331–332, 362*s*
 - Transcranial magnetic stimulation, 26–27*s*
 - Transcutaneous electrical nerve stimulation (TENS), 462
 - Transfer of learning. *See* Generalization
 - Transient ischemic attack (TIA), 87–88
 - Translation disorders, 52
 - Traumatic brain injuries (TBI)
 - anosognosia and, 228
 - axonal shearing in, 99*f*
 - causes of, 95
 - complicating conditions after, 148, 149, 150, 153, 154, 156*s*, 158
 - coup and contrecoup in, 99*f*
 - functional measures for, 284, 286
 - functional outcomes of, 66–72, 97, 100, 226
- From *Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice*, 2nd Ed., by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.

- participation measures for, 286
 - pathophysiological consequences of, 97–98, 99*f*, 100
 - patient interview and limitations from, 128
 - prevalence of, 94, 94*s*
 - prognostic factors in, 216*t*, 217, 219, 220, 221, 269, 270
 - psychiatric disorders screenings and, 160
 - quality-of-life measures for, 292
 - recovery stages in, 64–67
 - research funds for, 94*s*
 - risk factors in, 95
 - symptoms of, 67–72
 - types of, 95–97
- Traumatic brain injury screenings, 174
- Traumatic brain injury tests
- auditory comprehension, 196
 - cognitive abilities, 232, 238, 242, 243
 - cognitive-communication abilities, 185
 - dementia tests versus, 183, 184
 - discourse cohesion analysis in, 211
 - functional measures of, 281
 - lexical-semantic production, 198
 - overview of, 176–177*t*, 181–183
 - pragmatic and discourse abilities, 206, 208
- Traumatic brain injury treatment
- attention treatment, 363
 - CAM, 458, 460–461, 462, 463
 - communication partner training, 445–447
 - executive function treatment, 380, 383, 384
 - in groups, 437–438
 - memory treatment, 370, 371, 373, 374
 - pharmacotherapy approaches, 399*t*, 400*t*, 404–405, 406, 408
 - pragmatics and discourse impairment treatment, 341, 348, 349, 350
 - SFA, 324–326
 - suprasegmental impairments treatment, 304–307
- Treatment. *See specific approaches or treatments*
- Treatment confounds. *See Complicating conditions*
- Treatment efficacy. *See also Functional outcomes; specific approaches or treatments; specific treatment approaches and programs*, 9–10, 274, 279–283, 487
- Treatment efficiency. *See also Group treatment*, 10, 351, 487
- Treatment for Aphasic Perseveration (TAP)*, 381
- Treatment for Wernicke’s Aphasia (TWA), 311–312
- Treatment intensity, 354–355
- Treatment of underlying forms (TUF), 336–338
- Treatment outcomes. *See also Functional outcomes*, 19
- Treatment planning. *See also Ethnocultural variables*
- for bilingualism, 338–339*s*
 - different intervention strategies in, 328–329*s*
 - understanding theoretical framework behind, 300, 301*s*
 - use of case histories for, 124
 - use of patient and caregiver interviews for, 126, 128
- TUF. *See Treatment of underlying forms (TUF)*
- From *Neurogenic Disorders of Language and Cognition: Evidence-Based Clinical Practice*, 2nd Ed., by Laura L. Murray and Heather M. Clark, Austin, TX: PRO-ED. Copyright 2015 by PRO-ED, Inc.

Tumors. *See* Brain tumors
 Turn-taking issues, 71, 348, 442*t*, 446*t*
 TVCF. *See* *Test of Verbal Conceptualization and Fluency* (TVCF)
 TWA. *See* Treatment for Wernicke's Aphasia (TWA)
 Twitter, 443*s*
 TWT. *See* *The WORD Test—Second Edition: Adolescent* (TWT)

U

Unilateral spatial neglect. *See also* Neglect syndrome, 56

V

Validity, in formal tests. *See also* *specific tests*, 136–137
 VAMS. *See* *Visual Analog Mood Scales* (VAMS)
 Vanishing cues training approach. *See also* Chaining techniques, 375, 391
 Variation, generalization and, 392
 Vascular dementia. *See also* Dementia, 110–111, 219, 399*t*, 400*t*, 406, 408
 VASES. *See* *Visual Analogue Self-Esteem Scale* (VASES)
 VAST. *See* *Verb and Sentence Test* (VAST)
 VAT. *See* Visual Action Therapy (VAT)
 VATA-L. *See* *Visual-Analogue Test Assessing Anosognosia for Language* (VATA-L)
 VCIU. *See* Voluntary Control of Involuntary Utterances (VCIU)
 Vegetative state, 65–66
 Verbal asomatognosia, 59
 Verbal fluency tests, 263
 Verbal mediation training, 385, 424
 Verbal memory tests, 252–256
 Verbal organization, 369
 Verbal output, AAC and, 422
 Verbal span tasks, 253
Verb and Sentence Test (VAST), 202, 203, 204
 Verb Network Strengthening Treatment (VNeST). *See also* Semantic Feature Analysis (SFA), 326–328
 Vertebrobasilar arterial system, 80–81, 83–84
 Vestibular organ excitation, 359
 Veterans. *See also* Soldiers, 148
 Vibrotactile stimulation, 359
 Video recordings

- in awareness training, 377–378, 380
- in communication partner training, 447
- lexical-semantic treatments and, 314, 322
- in memory treatment, 368, 379*t*
- pragmatics and discourse-level impairments treatment and, 346, 348, 349

 Vietnamese speakers, 265
 Vigilance. *See* Sustained attention
Vigil Continuous Performance Test, 248
 Virtual Library Task (VLT), 242
 Virtual reality exercise program, 463
 Vision screenings, 148–149
 Visual Action Therapy (VAT), 417–418
 Visual agnosias, 55*t*, 152

Visual Analog Mood Scales (VAMS), 163
Visual Analogue Self-Esteem Scale (VASES), 163
Visual-Analogue Test Assessing Anosognosia for Language (VATA-L), 264
 Visual imagery. *See also* Guided imagery (GI), 361, 368–369
 Visual object agnosia, 152
 Visual perceptual deficits screenings, 151*t*, 152
 Visual Scene Displays (VSD), 419
 Visuospatial discrimination, Alzheimer’s disease and, 73
 Visuospatial environment, 449–450
 Visuospatial neglect. *See also* Hemi-inattention, 56
 VLT. *See* Virtual Library Task (VLT)
 VNeST. *See* Verb Network Strengthening Treatment (VNeST)
 Vocation, functional outcomes and, 226
 Vocational rehabilitation centers, 457
 Voluntary Control of Involuntary Utterances (VCIU), 317, 381
 Volunteers, 440, 441, 444
 VSD. *See* Visual Scene Displays (VSD)

W

WAB-R. *See* *Western Aphasia Battery–Revised (WAB-R)*
 WAIS-IV. *See* *Wechsler Adult Intelligence Scales (WAIS-IV)*
 Wandering, 450
 Watershed zones, 84
 WCST. *See* *Wisconsin Card Sorting Test (WCST)*
Wechsler Adult Intelligence Scales (WAIS-IV), 235, 253
Wechsler Memory Scale (WMS-IV), 240, 255, 256, 257
 Wellness activities. *See* Prevention and wellness activities
 Wernicke’s aphasia, 48*t*, 49, 221, 462
 Wernicke’s area, 28–29, 83, 103
Wessex Head Injury Matrix, 238
Western Aphasia Battery–Revised (WAB-R), 47, 173, 175, 177, 177*t*, 263
 West Nile Virus, 93–94
 Wheelbarrow test, 262
 WHO. *See* World Health Organization (WHO)
Wide Range Achievement Test–Fourth Edition, 198
Wilson Reading System, 303
 Wilson’s disease, 73*s*
Wisconsin Card Sorting Test (WCST), 259–260, 263
 WMS-IV. *See* *Wechsler Memory Scale (WMS-IV)*
 Women. *See* Gender differences
Woodcock Reading Mastery Tests–Third Edition (WRMT-III), 191, 207
 Word blindness. *See* Pure alexia
 Word deafness. *See* Pure word deafness
 Word meaning suppression, 62
 Word-picture matching, 302
 Word prediction, 420
 Word retrieval. *See also* Lexical-semantic processing, 76, 391
 Word retrieval error analyses, 199–201
 Workbooks, as treatment activities, 351–354, 388, 389*t*
 Working memory

- aphasia and, 44
 - definition of, 21*f*, 22–23
 - neural bases of, 31
 - as prognostic factor, 222
 - RHD and, 58
 - TBI and, 69
- Working memory tests, 253–256
- World Health Organization (WHO). *See* International Classification of Functioning, Disability, and Health (ICF)
- Writing treatment. *See* Orthographic treatment approaches
- Written language disruptions
- in aphasia, 38, 39*f*, 40–41, 42*t*
 - in dementia, 75, 76
 - neglect and, 250
 - orthographic processing and, 17
 - in Parkinson's disease, 108*f*
 - in RHD, 54, 58
 - social media use and, 443*s*
 - tests of, 192–193
- Written word–auditory word matching, 302
- WRMT-III. *See* Woodcock Reading Mastery Tests—Third Edition (WRMT-III)